Biocon and Equillium Announce Positive Phase 2 Results for Itolizumab in Ulcerative Colitis

Unknown Apr 02, 2026 900 Views

Biocon Limited and Equillium, Inc. have announced positive topline results from their Phase 2 study evaluating itolizumab in patients with moderate to severe ulcerative colitis. The study demonstrated clinical efficacy after 12 weeks of treatment, with itolizumab achieving a clinical remission ra...

Stay Ahead – Explore Now! FOMO TO FMA - Corporate Catalysts Meet Commodity Swings: Indian Markets Balance Opportunity and Global Volatility